GlassScriptPhysician profile
Suzanne Klutch
NPI 1659850170
$34,767.22
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $18K · 2023: $5,096 · 2024: $74.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,713 · Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,712.50 |
| Food and Beverage | $1,457.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,837.12 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,113.08 | 2022 | |
| Allergan, INC. | $2,605.34 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $399.92 | 2021 | |
| Novo Nordisk INC | $339.69 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $332.35 | 2021-2023 | Ajovy |
| Amgen INC. | $281.38 | 2021-2023 | Aimovig |
| Pfizer INC. | $224.76 | 2022-2023 | |
| Glaxosmithkline, LLC. | $166.65 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $118.19 | 2021-2023 | |
| Ucb, INC. | $70.42 | 2023-2024 | Nayzilam |
| Lilly USA, LLC | $69.56 | 2023 | Mounjaro, Emgality, Jardiance |
| Collegium Pharmaceutical, INC. | $38.45 | 2022 | |
| Edwards Lifesciences Corporation | $27.25 | 2023 | |
| Avanir Pharmaceuticals, INC. | $21.61 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.45 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.18 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.02 | 2021 | |
| Abbott Laboratories | $17.61 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $16.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Klutch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.